Literature DB >> 16157909

A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.

C P Zabetian1, A Samii, A D Mosley, J W Roberts, B C Leis, D Yearout, W H Raskind, A Griffith.   

Abstract

Referral-based studies indicate that a mutation (G2019S) in exon 41 of the LRRK2 gene might be a common cause of Parkinson disease (PD). The authors sequenced leucine-rich repeat kinase 2 (LRRK2) exons 31, 35, and 41 in 371 consecutively recruited patients with PD and found mutations in six (1.6%) subjects, including two heterozygous for new putative pathogenic variants (R1441H, IVS31 + 3A-->G). These data confirm the important contribution of LRRK2 to PD susceptibility in a clinic-based population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157909     DOI: 10.1212/01.wnl.0000172630.22804.73

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 2.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

3.  LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Authors:  Chen Yao; Rabih El Khoury; Wen Wang; Tara A Byrd; Elizabeth A Pehek; Colin Thacker; Xiongwei Zhu; Mark A Smith; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Neurobiol Dis       Date:  2010-04-09       Impact factor: 5.996

Review 4.  PARK8 LRRK2 parkinsonism.

Authors:  Kristoffer Haugarvoll; Zbigniew K Wszolek
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

5.  Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism.

Authors:  Owen A Ross; Cleanthe Spanaki; Alida Griffith; Chin-Hsien Lin; Jennifer Kachergus; Kristoffer Haugarvoll; Helen Latsoudis; Andreas Plaitakis; Joaquim J Ferreira; Cristina Sampaio; Vincenzo Bonifati; Ruey-Meei Wu; Cyrus P Zabetian; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2008-10-26       Impact factor: 4.891

6.  Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Cyrus P Zabetian; Shu-Ching Hu; Pinky Agarwal; Dora Yearout; Harvey Checkoway
Journal:  J Neural Transm (Vienna)       Date:  2016-06-27       Impact factor: 3.575

7.  Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS).

Authors:  Olena Korvatska; Nicholas S Strand; Jason D Berndt; Tim Strovas; Dong-Hui Chen; James B Leverenz; Konstantin Kiianitsa; Ignacio F Mata; Emre Karakoc; J Lynne Greenup; Emily Bonkowski; Joseph Chuang; Randall T Moon; Evan E Eichler; Deborah A Nickerson; Cyrus P Zabetian; Brian C Kraemer; Thomas D Bird; Wendy H Raskind
Journal:  Hum Mol Genet       Date:  2013-04-16       Impact factor: 6.150

8.  Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.

Authors:  Paola Costa-Mallen; Cyrus P Zabetian; Pinky Agarwal; Shu-Ching Hu; Dora Yearout; Ali Samii; James B Leverenz; John W Roberts; Harvey Checkoway
Journal:  Parkinsonism Relat Disord       Date:  2015-07-10       Impact factor: 4.891

9.  Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Authors:  Liang Huang; Mika Shimoji; Juan Wang; Salim Shah; Sukanta Kamila; Edward R Biehl; Seung Lim; Allison Chang; Kathleen A Maguire-Zeiss; Xiaomin Su; Howard J Federoff
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 10.  LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Authors:  Yulan Xiong; Valina L Dawson; Ted M Dawson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.